الموضوعات
Acenocoumarol/adverse effects , Acidosis, Lactic/blood , Anticoagulants/adverse effects , Aortic Valve Stenosis/surgery , Cyclooxygenase 2 Inhibitors/adverse effects , Diabetes Mellitus, Type 2/drug therapy , Drug Interactions , Female , Heart Valve Prosthesis Implantation , Humans , Hypoglycemic Agents/adverse effects , Lactones/adverse effects , Metformin/adverse effects , Middle Aged , Prothrombin Time , Sulfones/adverse effectsالملخص
Avaliou-se a eficácia de lactonas macrocíclicas (ivermectina e moxidectina) sobre a eventual ocorrência de efeitos colaterais e acompanharam-se, após a alta parasitológica, por 12 meses, os cães tratados, visando detectar a recidiva do quadro dermatopático. Dos 63 animais, 59 por cento eram fêmeas, 76 por cento apresentavam precisa definição racial e 67 por cento tinham pelame curto. A ivermectina (0,6mg/kg/dia) foi administrada por via oral a 31 cães, e a moxidectina (0,5mg/kg/cada 72 horas), pela mesma via, a 32 animais. Os tempos médios para a obtenção da primeira negativação do exame parasitológico do raspado cutâneo e para a consecução da alta foram, respectivamente, de 90 e 130 dias para a ivermectina e de 108 e 147 dias para a moxidectina. A ivermectina acarretou menos (16,1 por cento) efeitos colaterais em relação à moxidectina (37,5 por cento) (P=0,03). As recidivas foram, respectivamente, 10,3 por cento e 13 por cento para ivermectina e moxidectina. Não houve diferença entre os dois protocolos de terapia quanto aos percentuais de recidiva (P=0,67) e eficácia (P=0,61). Ambas as lactonas macrocíclicas mostraram-se eficazes: ivermectina 89,7 por cento e moxidectina 87 por cento.
The efficacy of ivermectin and moxidectin for treatment of generalized canine demodicosis, was evaluated to detect the eventual occurrence of side effects caused by the use of these drugs, and to follow the treated dogs for 12 months after obtaining parasitologic cure. Of 63 dogs, 59 percent were females, 76 percent were defined as purebred and 67 percent had short hair. Ivermectin (0.6mg/kg/daily) was orally administered to 31 dogs and moxidectin (0.5mg/kg/every 72 hours) to 32 dogs. The average number of days to obtain the first negative skin scraping results and the parasitologic cure were, respectively, 90 and 130 days for ivermectin, and 108 and 147 days for moxidectin. Ivermectin caused fewer side effects (16.1 percent) than moxidectin (37.5 percent) (P<0.05). The percentages of relapse were, respectively, 10.3 percent and 13.0 percent when ivermectin and moxidectin were administered. No difference between protocols of therapy was found for percentage of relapse (P> or =0.67) and efficacy (P> or =0.61). Both drugs were effective and safe to treat generalized canine demodicosis: ivermectin 89.7 percent and moxidectin 87.0 percent.
الموضوعات
Animals , Dogs , Ectoparasitic Infestations/prevention & control , Ectoparasitic Infestations/veterinary , Mite Infestations/prevention & control , Mite Infestations/veterinary , Lactones/administration & dosage , Lactones/adverse effectsالموضوعات
Cardiovascular System/drug effects , Cyclooxygenase 2 Inhibitors/adverse effects , Dose-Response Relationship, Drug , Female , Follow-Up Studies , Heart/drug effects , Humans , Hypertension/chemically induced , Incidence , Isoxazoles/adverse effects , Lactones/adverse effects , Male , Risk Assessment , Stroke/chemically induced , Sulfonamides/adverse effects , Sulfones/adverse effects , Survival Rateالموضوعات
Humans , Cardiovascular Diseases/chemically induced , Cyclooxygenase Inhibitors/adverse effects , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Lactones/adverse effects , Product Surveillance, Postmarketing , Pyrazoles/adverse effects , Risk Assessment , Sulfonamides/adverse effects , Sulfones/adverse effectsالملخص
Orlistat(Xenical(R), Roche) is considered a safe and effective drug to treat obesity by reduced absorption of 30% digested fat. To date, no serious adverse effects affecting the liver have been published except a case of subacute hepatic failure leading to liver transplantation in a young women with moderate obesity treated with orlistat. We report a case of acute cholestatic hepatitis in a young woman with moderate obesity treated with orlistat: a 33-year-old female admitted for the evaluation of jaundice. Abdominal ultrasonography, ERCP, routine chemistry, viral markers, and a fine needle biopsy of liver were performed. Microscopic findings of the liver biopsy specimen were compatible with acute cholestatic hepatitis. After steroid therapy, liver function was improved.